Clinical Trial

Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 13, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
A multicenter, open-label, prospective Phase III clinical trial to evaluate INR101 injection for PET/CT imaging in patients with Prostate Cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-03.
Trial Details
NCT Number NCT06922903
Lead Sponsor Yunhe Pharmaceutical (Tianjin) Co., Ltd
Conditions Prostate Cancer
Enrollment 240 participants
Start Date 2025-04
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2025-04-13